Canlyniadau Chwilio - Tawesak Tanwandee

Mireinio'r Canlyniadau
  1. 1
    Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence

    Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence gan Shadi Zerehpooshnesfchi, Amedeo Lonardo, Jian-Gao Fan, Reda Elwakil, Tawesak Tanwandee, Munira Y. Altarrah, Necati Örmecı, Mohammed Eslam

    Cyhoeddwyd 2025
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B

    Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B gan Teerha Piratvisuth, George Lau, You‐Chen Chao, Rui Jin, Anuchit Chutaputti, Q.-B. Zhang, Tawesak Tanwandee, Peter Button, M. Popescu

    Cyhoeddwyd 2008
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study

    Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study gan Teerha Piratvisuth, Tawesak Tanwandee, Satawat Thongsawat, Wattana Sukeepaisarnjaroen, Juan Ignacio Esteban, Marta Bes, Bruno Köhler, Ying He, Magdalena Lange, David Morgenstern, Henry Lik‐Yuen Chan

    Cyhoeddwyd 2021
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Assessing pricing and affordability of HBV treatment in Asia–Pacific region: a barrier to elimination

    Assessing pricing and affordability of HBV treatment in Asia–Pacific region: a barrier to elimination gan Jing Chen, Jidong Jia, Hui Zhuang, Wenhong Zhang, Jin Mo Yang, Tawesak Tanwandee, Diana Payawal, Saeed Hamid, Shiv Kumar Sarin, Masao Omata, Guiqiang Wang, George Lau

    Cyhoeddwyd 2025
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B

    52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B gan Teerha Piratvisuth, Piyawat Komolmit, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Henry Lik‐Yuen Chan, Mário G. Pessôa, E Fassio, Ono S, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Hugo Cheinquer, Rashidkhan Pathan, Yuhong Dong, Aldo Trylesinski

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy

    Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy gan Teerha Piratvisuth, Piyawat Komolmit, Henry C. B. Chan, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Mário G. Pessôa, E Fassio, Ono S, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Michael P. Manns, Alkaz Uddin, Yuhong Dong, Aldo Trylesinski

    Cyhoeddwyd 2016
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Liver Disease Trends in the Asia-Pacific Region for the Next 50 Years

    Liver Disease Trends in the Asia-Pacific Region for the Next 50 Years gan Shuichiro Shiina, Javkhlan Maikhuu, Deng Qing, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara‐Payawal, Rino Alvani Gani, Yi‐Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim

    Cyhoeddwyd 2025
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease

    Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease gan Yun–Fan Liaw, Joseph J.�Y. Sung, Wan Cheng Chow, Geoffrey C. Farrell, Cha‐Ze Lee, Hon K. Yuen, Tawesak Tanwandee, Qi-Min Tao, Kelly Shue, Oliver N. Keene, Jonathan S. Dixon, DF Gray, Jan Sabbat

    Cyhoeddwyd 2004
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study

    Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study gan Yun–Fan Liaw, M. Raptopoulou‐Gigi, Hugo Cheinquer, Shiv Kumar Sarin, Tawesak Tanwandee, Nancy Leung, Cheng‐Yuan Peng, Robert P. Myers, Robert S. Brown, Lennox J. Jeffers, Naoky Tsai, Jolanta Białkowska, Shijie Tang, S. P. Beebe, Elizabeth Cooney

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies

    Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies gan Teerha Piratvisuth, Jinlin Hou, Tawesak Tanwandee, Thomas Berg, Arndt Vogel, Jörg Trojan, Enrico N. De Toni, Masatoshi Kudo, Anja Eiblmaier, Hanns‐Georg Klein, Johannes Kolja Hegel, Kairat Madin, Konstantin Kroeniger, Ashish Sharma, Henry Lik‐Yuen Chan

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

    Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C gan Yun–Fan Liaw, Jidong Jia, Henry Lik‐Yuen Chan, Kyunghwa Han, Tawesak Tanwandee, Wan‐Long Chuang, Dianhui Tan, X. Y. Chen, Edward Gane, Teerha Piratvisuth, L. Chen, Qing Xie, Joseph J.�Y. Sung, Cynthia Wat, Coen Bernaards, Y. Cui, Patrick Marcellin

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

    A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma gan Shukui Qin, Stephen L. Chan, Wattana Sukeepaisarnjaroen, Guohong Han, Su Pin Choo, Virote Sriuranpong, Hongming Pan, Thomas Yau, Yabing Guo, Minshan Chen, Zhenggang Ren, Jianming Xu, Chia-Jui Yen, Zhong-Zhe Lin, Luigi Manenti, Yi Gu, Yongjian Sun, Ralph Tiedt, Lu Hao, Wenjie Song, Tawesak Tanwandee

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

    Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region gan Do Young Kim, Bao Nguyen Toan, Chee‐Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming‐Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce K. H. Chow, Rosmawati Mohamed, Stephen L. Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik‐Yuen Chan

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis

    Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis gan Jing Chen, Dong Ji, Jidong Jia, Hui Zhuang, Xinxin Zhang, Fusheng Wang, Wenhong Zhang, Xiaoguang Dou, Tawesak Tanwandee, Shiv Kumar Sarin, Rakhi Maiwall, Manoj Kumar, George Boon‐Bee Goh, Hasmik Ghazinyan, Anuchit Chutaputti, Pei‐Jer Chen, Hong You, Ming‐Lung Yu, Jacob George, Masao Omata, Gui‐Qiang Wang, George Lau

    Cyhoeddwyd 2025
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

    The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease gan Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai‐Sun Wong, Jian-Gao Fan, Takumi Kawaguchi, Sang Hoon Ahn, Ming‐Hua Zheng, Gamal Shiha, Yusuf Yılmaz, Rino Alvani Gani, Shahinul Alam, Yock Young Dan, Jia‐Horng Kao, Saeed Hamid, Ian Homer, Wah‐Kheong Chan, Diana A. Payawal, Soek‐Siam Tan, Tawesak Tanwandee, Leon A. Adams, Manoj Kumar, Masao Omata, Jacob George

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Editorial
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy

    Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy gan Manoj Kumar, Zaigham Abbas, Milad Azami, M. А. Belopolskaya, A. Kadir Dökmeci, Hasmik Ghazinyan, Jidong Jia, Ankur Jindal, Han Chu Lee, Lei Wei, Seng Gee Lim, Chun‐Jen Liu, Qiang Li, Mamun Al Mahtab, David Handojo Muljono, Madunil Anuk Niriella, Masao Omata, Diana A. Payawal, Shiv Kumar Sarin, Olivier Ségéral, Tawesak Tanwandee, Nirupma Trehanpati, Kumar Visvanathan, Jin Mo Yang, Man‐Fung Yuen, Yingjie Zheng, Yi‐Hua Zhou

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia

    An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia gan Michael Charlton, Altaf Alam, Akash Shukla, Bekhbold Dashtseren, Cosmas Rinaldi Adithya Lesmana, Davadoorj Duger, Diana A. Payawal, Cuong Duy, Ganbolor Jargalsaikhan, Ian Homer Yee, Jose D. Sollano, Karam Romeo Singh, Kaushal Madan, Khin Maung Win, Khin Pyone Kyi, Kyaw Soe Tun, Mohd. Salih, Mukul Rastogi, Neeraj Saraf, Phạm Thị Thu Thúy, Tran Dieu Hien Pham, Rino Alvani Gani, Rosmawati Mohamed, Tawesak Tanwandee, Teerha Piratvisuth, Wattana Sukeepaisarnjaroen, Win Naing, Zahid Yasin Hashmi

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

    APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy gan Lau, George, Yu, Ming-Lung, Wong, Grace, Thompson, Alexander, Ghazinian, Hasmik, Hou, Jin-Lin, Piratvisuth, Teerha, Jia, Ji-Dong, Mizokami, Masashi, Cheng, Gregory, Chen, Guo-Feng, Liu, Zhen-Wen, Baatarkhuu, Oidov, Cheng, Ann Lii, Ng, Woon Leung, Lau, Patrick, Mok, Tony, Chang, Jer-Ming, Hamid, Saeed, Dokmeci, A. Kadir, Gani, Rino A., Payawal, Diana A., Chow, Pierce, Park, Joong-Won, Strasser, Simone I., Mohamed, Rosmawaiti, Win, Khin Maung, Tawesak, Tanwandee, Sarin, Shiv Kumar, Omata, Masao

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn Cael y testun llawn
    Text
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

    APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis gan Hong You, Xiong Ma, Cumali Efe, Guiqiang Wang, Sook‐Hyang Jeong, Kazumichi Abe, Weijia Duan, Sha Chen, Yuanyuan Kong, Dong Zhang, Lai Wei, Fu‐Sheng Wang, Han‐Chieh Lin, Jin Mo Yang, Tawesak Tanwandee, Rino Alvani Gani, Diana A. Payawal, Barjesh Chander Sharma, Jinlin Hou, Osamu Yokosuka, A. Kadir Dökmeci, Dorothy H. Crawford, Jia‐Horng Kao, Teerha Piratvisuth, Dong Jin Suh, Laurentius A. Lesmana, Jose D. Sollano, George Lau, Shiv Kumar Sarin, Masao Omata, Atsushi Tanaka, Jidong Jia

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Editorial
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries

    Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries gan Jin-Lin Hou, Wei Zhao, Changhyeong Lee, Hie-Won Hann, Cheng‐Yuan Peng, Tawesak Tanwandee, Viacheslav Morozov, Hartwig Klinker, Jose D. Sollano, Adrian Streinu‐Cercel, Hugo Cheinquer, Qing Xie, Yu‐Ming Wang, Lai Wei, Jidong Jia, Guozhong Gong, Kwang‐Hyub Han, Wukui Cao, Mingliang Cheng, Xiaoping Tang, Deming Tan, Hong Ren, Zhongping Duan, Hong Tang, Zhiliang Gao, Shijun Chen, Shumei Lin, Jifang Sheng, Cheng‐Wei Chen, Jia Shang, Tao Han, Yanyan Ji, Junqi Niu, Jian Sun, Yongpeng Chen, Elizabeth Cooney, Seng Gee Lim

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: